Kamada Ltd. (KMDA)
7.24
0.04 (0.56%)
At close: Jan 14, 2025, 3:59 PM
7.30
0.83%
After-hours Jan 14, 2025, 05:59 PM EST
undefined% (undefined)
| Bid | 7 |
| Market Cap | 416.20M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0.27 |
| PE Ratio (ttm) | 26.81 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 7.3 |
| Volume | 119,246 |
| Avg. Volume (20D) | 70,406 |
| Open | 7.27 |
| Previous Close | 7.20 |
| Day's Range | 7.05 - 7.39 |
| 52-Week Range | 4.74 - 8.00 |
| Beta | undefined |
About KMDA
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurre...
Sector Healthcare
IPO Date May 31, 2013
Employees 378
Stock Exchange NASDAQ
Ticker Symbol KMDA
Website https://www.kamada.com
Analyst Forecast
According to 2 analyst ratings, the average rating for KMDA stock is "Buy." The 12-month stock price forecast is $14.5, which is an increase of 100.28% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Kamada Ltd. is scheduled to release its earnings on Mar 5, 2025,
before market opens.
Analysts project revenue of $39.59M, reflecting a 8.67% YoY growth and earnings per share of 0.06, making a -33.33% decrease YoY.
Analysts project revenue of $39.59M, reflecting a 8.67% YoY growth and earnings per share of 0.06, making a -33.33% decrease YoY.
6 days ago ·
Source
+7.65%
Kamada shares are trading higher after the company...
Unlock content with
Pro Subscription
